Is EXPL undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of EXPL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EXPL (€190) is trading below our estimate of fair value (€379.56)
Significantly Below Fair Value: EXPL is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EXPL?
Key metric: As EXPL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
The above table shows the Price to Earnings ratio for EXPL. This is calculated by dividing EXPL's market cap by their current
earnings.
What is EXPL's PE Ratio?
PE Ratio
18.8x
Earnings
€21.30m
Market Cap
€398.59m
EXPL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Earnings vs Industry: EXPL is expensive based on its Price-To-Earnings Ratio (18.8x) compared to the European Chemicals industry average (17.1x).
Price to Earnings Ratio vs Fair Ratio
What is EXPL's PE Ratio
compared to its
Fair PE Ratio?
This is the expected PE Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
EXPL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio
18.8x
Fair PE Ratio
14.6x
Price-To-Earnings vs Fair Ratio: EXPL is expensive based on its Price-To-Earnings Ratio (18.8x) compared to the estimated Fair Price-To-Earnings Ratio (14.6x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.